Skip to main content
Fig. 10 | Journal of Experimental & Clinical Cancer Research

Fig. 10

From: Peglated-H1/pHGFK1 nanoparticles enhance anti-tumor effects of sorafenib by inhibition of drug-induced autophagy and stemness in renal cell carcinoma

Fig. 10

Schematic illustration of HGFK1 and sorafenib exhibiting synergistic anti-tumor effects on RCC. In brief, sorafenib could induce autophagy via activating NF-κB signaling pathway, and then enhance the cancer stemness of RCC resulting in drug resistance. But HGFK1 could inhibit the activation of NF-κB induced by sorafenib

Back to article page